Biotech Values

[DewDiligence]

NTRP reverse-merges into—(private)—Metuchen Pharmaceuticals, which will be renamed, Petros Pharmaceuticals:

https://www.prnewswire.com/news-releases/neurotrope-and-metuchen-pharmaceuticals-announce-merger-agreement-to-form-petros-pharmaceuticals-a-mens-health-company-301060769.html

Neurotrope, Inc…and Metuchen Pharmaceuticals, L.L.C., a privately held biopharmaceutical company…focused on identifying, developing, acquiring, and commercializing innovative therapeutics for men's health conditions, today announced that the two companies have entered into a definitive merger agreement under which Metuchen and Neurotrope, Inc. will merge in an all-stock transaction resulting in a newly formed holding company to be renamed Petros Pharmaceuticals, Inc. ("Petros").

Petros is expected to become a Nasdaq traded company focused solely on men's health conditions. Petros' cornerstone product would be Metuchen's Stendra (avanafil) for erectile dysfunction ("ED"). Petros' pipeline would include Metuchen's recently in-licensed product H-100 for Peyronie's disease, and it would include a business development program exploring various men's health products, including endothelial dysfunction, prostate cancer, psychosexual and psychosocial ailments, hormone health and substance use disorders.

…it is anticipated that existing Neurotrope shareholders will own approximately 20% and Metuchen shareholders will own approximately 80% of the combined company…

…Upon closing of the transaction, Neurotrope Bioscience Inc.'s current lead asset, Bryostatin-1 to treat neurodegeneration, and substantially all of its existing assets, operations and liabilities, except for cash retained by Petros in accordance with the terms of the merger agreement, will be spun-out into a new, separately traded company.

This kind of immediate spin-out is unusual in a reverse-merger.